1: Lulli D, Carbone ML, Pastore S. The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes. Int J Mol Sci. 2017 Oct 24;18(10). pii: E2227. doi: 10.3390/ijms18102227. PubMed PMID: 29064427.

2: Ferguson PJ, Vincent MD, Koropatnick J. Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein. J Pharmacol Exp Ther. 2017 Oct 23. pii: jpet.117.241661. doi: 10.1124/jpet.117.241661. [Epub ahead of print] PubMed PMID: 29061656.

3: Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.384. [Epub ahead of print] PubMed PMID: 29059158.

4: Sun M, Xu Y, Huang J, Jiang Z, Shu H, Wang H, Zhang S. Global Identification, Classification, and Expression Analysis of MAPKKK genes: Functional Characterization of MdRaf5 Reveals Evolution and Drought-Responsive Profile in Apple. Sci Rep. 2017 Oct 18;7(1):13511. doi: 10.1038/s41598-017-13627-2. PubMed PMID: 29044159.

5: Vuong HG, Altibi AM, Duong UN, Ngo HT, Pham TQ, Tran HM, Oishi N, Mochizuki K, Nakazawa T, Hassell L, Katoh R, Kondo T. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. Tumour Biol. 2017 Oct;39(10):1010428317713913. doi: 10.1177/1010428317713913. PubMed PMID: 29037127.

6: Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, Dai Y, Xie Y, Lin H, Liang X, Cai X. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Med. 2017 Oct 13. doi: 10.1002/cam4.1228. [Epub ahead of print] PubMed PMID: 29030911.

7: Hu MH, Chen LJ, Chen YL, Tsai MS, Shiau CW, Chao TI, Liu CY, Kao JH, Chen KF. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089. doi: 10.18632/oncotarget.17779. eCollection 2017 Sep 12. PubMed PMID: 29029413; PubMed Central PMCID: PMC5630313.

8: Juárez M, Egoavil C, Rodríguez-Soler M, Hernández-Illán E, Guarinos C, García-Martínez A, Alenda C, Giner-Calabuig M, Murcia O, Mangas C, Payá A, Aparicio JR, Ruiz FA, Martínez J, Casellas JA, Soto JL, Zapater P, Jover R. KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. PLoS One. 2017 Sep 27;12(9):e0184937. doi: 10.1371/journal.pone.0184937. eCollection 2017. PubMed PMID: 28953955; PubMed Central PMCID: PMC5617162.

9: Barrette AM, Bouhaddou M, Birtwistle MR. Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. ACS Chem Neurosci. 2017 Oct 6. doi: 10.1021/acschemneuro.7b00197. [Epub ahead of print] PubMed PMID: 28950062.

10: Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Grève J. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Oncotarget. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep 1. PubMed PMID: 28947956; PubMed Central PMCID: PMC5601124.

11: Toress-Collado AX, Nazarian R, Jazirehi AR. Rescue of cell cycle progression in BRAF(V600E) inhibitor-resistant human melanoma by a chromatin modifier. Tumour Biol. 2017 Sep;39(9):1010428317721620. doi: 10.1177/1010428317721620. PubMed PMID: 28936920.

12: Sutton BC, Birse RT, Maggert K, Ray T, Hobbs J, Ezenekwe A, Kazmierczak J, Mosko M, Kish J, Bullock A, Shi Z, Stack MS, Irwin D. Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX® HS, a new highly sensitive assay for the MassARRAY® System. PLoS One. 2017 Sep 19;12(9):e0183715. doi: 10.1371/journal.pone.0183715. eCollection 2017. PubMed PMID: 28926605; PubMed Central PMCID: PMC5604939.

13: Aida S, Sonobe Y, Tanimura H, Oikawa N, Yuhki M, Sakamoto H, Mizuno T. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor. Cancer Lett. 2017 Nov 28;409:116-124. doi: 10.1016/j.canlet.2017.09.008. Epub 2017 Sep 18. PubMed PMID: 28923400.

14: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11. PubMed PMID: 28919011.

15: Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, Davies BR, Collins AT, Maitland NJ. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget. 2017 May 23;8(34):56698-56713. doi: 10.18632/oncotarget.18082. eCollection 2017 Aug 22. PubMed PMID: 28915623; PubMed Central PMCID: PMC5593594.

16: Buffet C, Hecale-Perlemoine K, Bricaire L, Dumont F, Baudry C, Tissier F, Bertherat J, Cochand-Priollet B, Raffin-Sanson ML, Cormier F, Groussin L. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. PLoS One. 2017 Sep 14;12(9):e0184861. doi: 10.1371/journal.pone.0184861. eCollection 2017. PubMed PMID: 28910386; PubMed Central PMCID: PMC5599027.

17: Wang H, Zou L, Ma K, Yu J, Wu H, Wei M, Xiao Q. Cell-specific mechanisms of TMEM16A Ca(2+)-activated chloride channel in cancer. Mol Cancer. 2017 Sep 11;16(1):152. doi: 10.1186/s12943-017-0720-x. Review. PubMed PMID: 28893247; PubMed Central PMCID: PMC5594453.

18: Shibata S, Furuta K, Oh-Hashi K, Ueda H, Kiuchi K, Hirata Y. Prevention of oxytosis-induced c-Raf down-regulation by (arylthio)cyclopentenone prostaglandins is neuroprotective. Toxicology. 2017 Sep 1;390:83-87. doi: 10.1016/j.tox.2017.09.006. Epub 2017 Sep 6. PubMed PMID: 28888848.

19: Ryall S, Arnoldo A, Krishnatry R, Mistry M, Khor K, Sheth J, Ling C, Leung S, Zapotocky M, Guerreiro Stucklin A, Lassaletta A, Shago M, Tabori U, Hawkins CE. Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System. J Neuropathol Exp Neurol. 2017 Jul 1;76(7):562-570. doi: 10.1093/jnen/nlx042. PubMed PMID: 28863456.

20: Karamzadeh Dashti N, Bahrami A, Lee SJ, Jenkins SM, Rodriguez FJ, Folpe AL, Boland JM. BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics. Am J Surg Pathol. 2017 Nov;41(11):1532-1541. doi: 10.1097/PAS.0000000000000913. PubMed PMID: 28834810.